Spago Nanomedical
2.12.2021 11:01:32 CET | ACCESS Newswire | Press release
LUND, SWEDEN / ACCESSWIRE / December 02, 2021 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F)
Spago Nanomedical AB (publ) today annouced that all patients have been recruited in the second dose group in the company's ongoing clinical phase I study SPAGOPIX-01 with the tumor-selective contrast agent SpagoPix (SND132D). New interim results are expected to be reported in early 2022.
A total of 6 patients with confirmed breast cancer have been included in the second dose group in the phase I study SPAGOPIX-01, which has been performed at two hospitals in Sweden. A number of adjustments to the study protocol have been made during the course of the study to, among other things, broaden the patient base and simplify the inclusion of patients. Including the 6 patients included in the first dose group, a total of 12 patients were evaluated in the study.
"It is very gratifying that we have now completed the recruitment and can start analyzing the results from the second patient group who received a higher dose of our tumor selective contrast agent SND132D", said Mats Hansen, CEO of Spago Nanomedical. "We have seen that SND132D is well tolerated by patients in lower doses, where early signals of contrast enhancement have also been shown. It will be exciting to get the results from the analysis of this dose group at the beginning of next year."
The primary endpoint of the study is to study safety at different doses of SN132D. Secondary endpoints include initially investigating how the contrast agent can enhance MRI images in clinical use in patients with solid tumors of the breast, as well as the liver and the pancreas.
Previous interim results from the study have shown a good safety profile and clear contrast in MRI images of breast tumors at the current dose. Furthermore, all images in the study showed a very good contrast in the pancreas and in the liver.
For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se
Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.
FNCA Sweden AB is the Certified Adviser of the company, +46 8 528 00 399, info@fnca.se .
This information is information that Spago Nanomedical is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-12-02 10:34 CET.
Attachments
Second dose group fully recruited in Spago Nanomedical's phase 1 study with SpagoPix
SOURCE: Spago Nanomedical
View source version on accesswire.com:
https://www.accesswire.com/675695/Second-Dose-Group-Fully-Recruited-in-Spago-Nanomedicals-Phase-1-Study-with-SpagoPix
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
RE Royalties Launches $5 Million Series 5 Green Bond Offering and Provides Strategic Growth Update4.11.2026 00:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 3, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQB:RROYF)(FSE:Y2V) ("RE Royalties" or the "Company") is pleased to announce the launch of its fifth secured Green Bond offering, seeking to raise up to $5 million to support the continued growth of its renewable energy royalty portfolio. Building on the success of its previous Green Bond issuances, the Company will offer Series 5 secured Green Bond Units through a non-brokered private placement of Series 5 secured green bond units (the "Green Bond Units") at the price of either $1,000 or US$1,000 per Green Bond Unit for gross proceeds of up to $5,000,000 (the "Private Placement Offering"). Each Green Bond Unit will be comprised of $1,000 or US$1,000 principal amount of green bonds (the "Green Bonds") and 1,000 common share purchase warrants (each a "Warrant"). For the purposes of calculating the Private Placement Offering's aggregate gross proceeds, issuances of the United States dollar denominated Gree
OMP Extends UnisonIQ with Agent Library and Agent Studio: AI Agents that Produce Executable Supply Chain Plans3.11.2026 15:00:00 CET | Press release
ANTWERPEN, BE / ACCESS Newswire / November 3, 2026 / OMP, a leader in supply chain orchestration, today extended UnisonIQ, the AI framework in its Unison Planning™ platform, with the Agent Library of ready-to-deploy AI agents and Agent Studio, where companies build their own. The agents run on the optimization engines in Unison Planning™ and produce executable supply chain plans. Bekaert is among the early adopters of UnisonIQ. Supply chain organizations face board-level pressure to show progress on AI, but many struggle to move beyond experiments. Generic AI models and decision-intelligence tools miss the industry-specific context and semantics that planning depends on, while planning tools with an AI layer on top lack reasoning depth. Both can produce a confident answer that ignores real-world constraints such as shelf life, co-products, and shared capacity. In UnisonIQ, by contrast, each agent works from a reality-based digital twin of the customer's own supply chain and calls on th
Fermi Provides Update on Lease Agreement as Parties Work Toward Closing3.11.2026 13:00:00 CET | Press release
DALLAS, TX / ACCESS Newswire / November 3, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), today issued the following statement on the Data Center Lease and Services Agreement (the "Lease") between its wholly owned subsidiary, Fermi Campus 1 LLC, and TensorWave TEX1, LLC ("TensorWave"), after the October 31, 2026 closing date passed without extension. "Both Fermi and TensorWave remain committed to this lease, and we are continuing to work through the remaining conditions prior to close," said Lee McIntire, Fermi Chief Executive Officer. "We expect to provide more information on the discussions during our earnings call next week, or sooner if appropriate." The Lease, signed in August 2026, provides that its effectiveness is subject to the satisfaction or waiver of specified closing conditions. Those conditions include executing and delivering related work letters and guaranties; finalizing operations schedules and a service-level agreem
IXOPAY Announces IXO One, a Modular Payments Platform Built for an Era of Fluid Commerce3.11.2026 10:00:00 CET | Press release
DALLAS, TX / ACCESS Newswire / November 3, 2026 / IXOPAY, the leader in payment infrastructure enabling fluid commerce, today announced the launch of IXO One, an AI-native, modular payment platform that unifies orchestration, payments intelligence, and tokenization. It gives merchants the flexibility to buy what they need, build what they want, and adapt as commerce evolves. Built to power an era of fluid commerce and technology-driven payment experiences, IXO One provides the dynamic infrastructure needed to adapt quickly without ripping out or replacing their current payment stack. Traditional payment infrastructure makes it difficult for merchants to embrace fluid commerce and a rapidly changing payment market. From fragmented systems to rigid provider relationships, a new opportunity can require a heavy integration lift, slow time-to-market, and increased costs. IXO One's modular platform helps merchants mitigate the payment friction that leads to provider dependency, expensive mig
Chervon Promotes Soobia Haroon to Vice President, Human Resources - NA2.11.2026 15:00:00 CET | Press release
NAPERVILLE, IL / ACCESS Newswire / November 2, 2026 / Chervon promotes Soobia Haroon to Vice President, Human Resources - NA, effective November 2, 2026, reporting to Joe Galli, CEO. Over the past two years, Haroon has been a key member of the Chervon Senior Executive Team, driving talent acquisition, organizational development, and transformation. She has provided strategic leadership across all HR functions while strengthening corporate HR strategy, governance, and processes to support the company's objectives and continued growth. Before joining Chervon, Soobia progressed through a series of human resources positions at several multinational companies. Her HR experience is strong in supporting many functional areas, including supply chain, distribution, manufacturing, IT, engineering, product management, marketing, and finance. "Soobia has been instrumental in our aggressive talent acquisition initiative since I joined Chervon," said Joe Galli. "Her extensive HR experience, her sens
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom